GleamWall
中文EN

EXOZ EXOZYMES INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2010788 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-21.6%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-268.1%
ROA-149.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-41.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.62M$1.44M$1.12M$1.11M$1.22M$802,991$575,016$630,303
SG&A expense$1.43M$1.52M$1.27M$1.58M$1.31M$1.75M$1.38M$1.35M
Operating income-$3.05M-$2.95M-$2.39M-$2.70M-$2.52M-$2.55M-$1.95M-$1.98M
Pretax income-$2.24M-$2.88M-$2.37M-$2.76M-$2.29M-$2.36M-$1.86M-$1.84M
Net income-$2.24M-$2.88M-$2.37M-$2.66M-$2.29M-$2.36M-$1.86M-$1.84M
EBITDA-$2.96M-$2.88M-$2.31M-$2.62M-$2.45M-$2.48M-$1.88M-$1.92M
EPS (basic)-0.24-0.33-0.28—-0.27-0.28-0.22—
EPS (diluted)-0.24-0.33-0.28—-0.27-0.28-0.22—
Weighted avg. shares (diluted)9.29M8.66M8.46M—8.39M8.38M8.37M—
Balance sheet
Cash & equivalents$3.26M$5.65M$1.44M$3.04M$5.10M$6.99M$8.51M$9.72M
Current assets$3.91M$6.17M$2.09M$3.94M$5.61M$7.53M$9.42M$10.82M
PP&E, net$895,929$670,908$747,858$764,401$763,012$821,305$842,990$882,445
Total assets$5.86M$7.98M$4.02M$5.97M$7.72M$9.68M$11.53M$13.03M
Current liabilities$1.70M$1.62M$1.58M$1.57M$1.24M$1.22M$1.44M$1.33M
Total liabilities$3.67M$4.33M$2.49M$2.57M$2.34M$2.44M$2.64M$2.61M
Shareholders' equity$2.19M$3.65M$1.53M$3.40M$5.37M$7.24M$8.88M$10.42M
Shares outstanding9.30M9.28M8.48M8.41M8.39M8.39M8.37M8.37M
Cash flow statement
Operating cash flow-$2.22M-$1.64M-$1.52M-$1.97M-$1.86M-$1.54M-$1.13M-$5.71M
Capital expenditure$309,980-$1$57,604$74,988$13,310$50,573$31,046$210,406
Free cash flow-$2.53M-$1.64M-$1.58M-$2.05M-$1.87M-$1.59M-$1.16M-$5.92M
Investing cash flow-$164,765$1-$57,604-$74,990-$13,308-$30,874-$31,046-$210,407
Financing cash flow-$7,407$5.85M-$12,736-$10,554——-$43,254$15.40M
Depreciation & amortization$84,959$76,949$74,147$73,599$71,603$72,256$70,503$67,567
Stock-based compensation$775,871$1.22M$501,098$677,866$425,708$567,254$317,277$317,277

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.